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Background: Over 2,300 patients were seen in the Harris Health System for 
anticoagulation management in 2012. Due to high patient volume and limited 
appointments, many patients cannot be seen in a timely manner. Efforts have been made 
to increase anticoagulation visits, such as increasing the number of appointments for 
clinical pharmacy specialists (CLPS).  Also, a telephone management service was 
established for clinical staff pharmacists (CSPs) to provide anticoagulation management. 
 
Objective: The primary objective is to assess the total number of visits per month before 
and after increased pharmacist utilization. Secondary objectives include time to 3rd 
available appointment, proportion of patients in therapeutic range at 30 days, and 30 day 
readmission due to anticoagulation adverse effects pre and post intervention. 
 
Methods: Prior to the initiation of the study, Institutional Review Board (IRB) approval 
was obtained, along with a waiver of informed consent. This is a retrospective cohort 
study using a quasi-experimental design.  To be included in this study, patients must have 
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been seen by the clinical pharmacy specialist. The data will be collected from the time 
period of October 1, 2011 to April 1, 2014 for four clinics within the Harris Health 
System. In addition, a secondary analysis will evaluate productivity for the CLPS by 
evaluating the number of completed publications and projects pre and post intervention. 
We will also evaluate the pharmacy productivity standards per month for the four piloted 
clinics pre and post intervention for CSPs.    
 
Results: Piloted clinics increased anticoagulation visits from 134 patients to 143 patients 
monthly. However, this result was not statically significant. Time to third available 
appointment decreased from 12 days to 7 days, which was not statistically significant 
(p=0.03).  This was due to a noted statistical decrease at the Northwest Clinic. No 
changes in time in therapeutic range and readmissions were noted. No difference was 
noted in clinics based on productivity, which was defined as work hours over prescription 
volume. In addition, no difference was noted on amount of projects completed by CLPS. 
 
Conclusions: Results show increase access to care during the post intervention period. 
However, visits did not increase as predicted. Time to appointment and high quality 
clinical outcomes were maintained. More research should be completed to further 
evaluate expanding coverage through the use of CSPs.     
 
  
8 
 
 
 
Table of Contents: 
 
I. Abstract        Page 6 
II. Background      Page 9 
III. Objectives       Page 13 
IV. Hypothesis      Page 14 
V. Study Design      Page 14 
VI. Methods       Page 15 
VII. Results       Page 17 
VIII. Conclusion      Page 19 
IX. Acknowledgements     Page 23 
X. Disclosures      Page 24 
XI. Figures       Page 26 
XII. References       Page 38 
 
List of Figures, Tables and Appendixes: 
 
Appendix 1: Enrollment of Patients in Telephone Service  Page 26 
Appendix 2: Removal of Patient from Telephone Enrollment Page 27 
Figure 1: Treatment Arms      Page 28 
Figure 2: Total Number of Visits     Page 29 
Table 1: Total Number of Anticoagulation Visits   Page 30 
Table 2: CLPS Time to Third Available Appointment (Days) Page 31 
Table 3: Baseline Characteristics     Page 32 
Table 4: Baseline Anticoagulation Characteristics   Page 33 
Figure 1: Time in Therapeutic Range  (TTR)    Page 34 
Figure 2: Hospitalizations due to Thromboembolic event or bleed Page 35 
Table 5: CSP Productivity (Work Hours/Volume)   Page 36 
Figure 3: CLPS Projects      Page 37 
Appendix 3: Telephone Service     Page 38 
 
List of Acronyms: 
 
ASHP: American Society of Health-System Pharmacists 
CLPS: Clinical Pharmacy Specialists 
CSP: Clinical Staff Pharmacist  
PPMI: Pharmacy Practice Model Initiative  
EMR: Electronic Medical Record 
INR: Internalized Normal Ratio 
TTR: Time in Therapeutic Range 
 
 
 
  
9 
 
 
 
 
Background Information: 
 
Clinical pharmacists play an essential role in the management of patients with chronic 
diseases by optimizing treatment outcomes. They increase the rate of achieving 
therapeutic goals and decrease the cost of therapy for both patients and health care 
settings
1
. For example, a retrospective study performed in the medical home setting 
showed that patients receiving care from the clinical pharmacist had about a threefold 
increased likelihood of achieving an A1c less than 7% compared with patients receiving 
usual care
1
. Another study evaluated a centralized pharmacy specialist–managed program 
that was successful in assisting patients achieve their lipid goals where 72.9% achieved 
the LDL-C goal of 100 mg/dL
2 
. 
 
Anticoagulation therapy is used in the inpatient and outpatient setting to prevent venous 
and arterial thrombosis in patients. This includes the use of vitamin K antagonists, such 
as warfarin and low molecular weight heparin, such as enoxaparin. Treatment goals are 
set to obtain an INR within therapeutic range. There is a strong association between INR 
levels outside the therapeutic range and adverse outcomes. An INR of < 2.0 can result in 
increased risk of ischemic stroke, and an INR of > 4.0 can result in the increased risk of 
hemorrhage. Therefore, it is essential to maximize the time spent within therapeutic INR 
range. A wide variation in percentage of TTR, 29%–75%, has been reported3. Warfarin 
use is the one of the most common cause of adverse drug events in emergency rooms 
with an average risk of major bleeding due to warfarin of 15–20% per year4. Therefore, 
frequent monitoring and therapy adjustment are essential for these patients. However, due 
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to the complexity of anticoagulation management, many patients are not managed 
appropriately. Clinical pharmacy services have shown to be effective in anticoagulation 
monitoring
5
. Clinical pharmacists have been shown to be equal or superior to experienced 
physicians and other healthcare providers in managing patients on warfarin
5
. A study 
conducted at Kaiser Permanente Colorado Region compared patients whose 
anticoagulation therapy was managed by a physician group vs. a telephone service 
provided by the Clinical Pharmacy Anticoagulation Service
5
. The study concluded that 
using the telephone service resulted in a higher likelihood of achieving target INR range 
(63.5%) compared to the control group (55.2%) and reduced the risk of major bleeding
5
.  
 
While clinical pharmacy services have shown great potential, certain limitations still 
remain as pharmacists are faced with a number of challenges. A study conducted at 
Veteran Health Affairs mentioned that limitations included: lack of time; high workload; 
staff shortages; compensation issues and poor physician collaboration
6
. Some of these 
limitations can be seen within Harris Health system.  The Harris Health System is a fully 
integrated healthcare system which provides patient care for residents of Harris County in 
and around Houston, Texas.  The system includes 16 community health centers and two 
full-service hospitals.  The majority of patients seen within the health system are indigent 
or charity care. Last year, Harris Health System provided more than $1.25 billion in 
charity care. 
 
The Harris Health System pharmacy department is comprised of pharmacy technicians, 
CSPs and CLPS in both the inpatient and outpatient settings. In the outpatient setting, 
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CLPS provide chronic disease management through face to face patient encounters for 
chronic diseases including but not limited to, anticoagulation, diabetes, hypertension and 
hyperlipidema. The CLPS see at least sixteen patients per day. From July 2012 to 
September 2012 there were over 5,600 outpatient CLPS visits with more than 2,300 of 
the visits for anticoagulation management.  Not all patients are followed up by CLPS in 
the recommended time frame due to lack of appointment availability secondary to high 
patient volume. For example, from November 2011 to November 2012 roughly 778 
patients were discharged with a warfarin order after leaving the hospital. To appropriately 
monitor the patient’s INR, the individual should be seen within 7 days post discharge. Of 
these 778 patients only 433 were seen within 7 days. Therefore, roughly 45% of patients 
were not seen by CLPS within the appropriate time frame. However, due to limitations on 
funding and space, hiring an increased number of CLPS remains a challenge.  
 
Efforts have been made to increase utilization of pharmacists in the outpatient setting. 
CLPS in the past did not have scheduled patient visits on Fridays.  Fridays were used for 
staff meetings, student topic discussions, and time allotted to additional projects. To 
increase visit access, two half days of visits per month were added to the clinic sites to 
increase appointment availability beginning April 2013. This would allow for an 
additional 16 to 24 patient visits per month. 
 
CSPs in the outpatient setting provide distributive, dispensing function support for the 
pharmacy but are underutilized in the clinical role. This differs from the CLPS who see 
patients face to face.  However, with a projected shortage of primary care providers, there 
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is an unprecedented opportunity for these CSPs to expand access to care in the areas of 
chronic disease management and preventative medicine.  
 
A recent trial published reviewed anticoagulation clinics in the Veterans Affair health 
care clinics. The study reviewed clinics which were categorized as low performing clinics 
or high performing clinics, and analyzed factors that could have contributed to the clinics 
success or failure
7
. When comparing a clinic visit with a telephone service, the study 
noted that no difference was displayed.  
 
For this clinical pharmacy service, the clinical outpatient pharmacy team and outpatient 
pharmacy operations team collaborated to implement a pharmacist telephone encounter 
service designed to help monitor patients on warfarin. This service was staffed by a CSP.  
 
The telephone clinical program was implemented at Northwest, Strawberry, Settegast, 
and Acres Clinics within the Harris Health System in April 2013. CLPS trained the CSPs 
participating in the telephone service on anticoagulation education, therapy adjustments 
and documentation.  
 
This study is unique in that the clinical pharmacy services provided were conducted by 
both the clinical pharmacy specialists and clinical staff pharmacists. These services were 
be provided to the patients of the Harris Health system, who are primarily charity care 
and the indigent population. 
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This study assessed the outcomes associated with an anticoagulation service involving 
increasing utilization of outpatient pharmacists at Acres, Settegast, Northwest and 
Strawberry clinics.  
 
 Objectives: 
The objective of this project is to assess if increased utilization of pharmacists, CLPS and 
CSP, allows for the expansion of the number of anticoagulation visits and expand CSP 
services.  
 
The specific objectives of this study are to compare the following data pre and post 
intervention: 
 
 Quantitative measures 
  Total number of anticoagulation visits per month 
  Time to third available appointment 
  TTR at 30 days 
  Readmission due to thromboembolic event or bleed 
  Productivity based on work hours over prescription volume 
 Number of projects completed by CLPS  
 
Furthermore, the study will allow the department to identify obstacles and challenges to 
evaluate the future steps needed for increasing anticoagulation visits through utilization 
of outpatient pharmacists.  
14 
 
 
 
 
Hypothesis: 
 
This study will show that increased utilization of pharmacy services will increase the 
number of patient visits by approximately 20%.  Also, this study will show that the time 
to 3rd available appointment, which corresponds to the time until the 3rd next available 
appointment for CLPS, will not be increased even though new patients are being added. 
Ultimately, we believe that the changes in time to 3rd available appointment from the 
current baseline will not be statistically significant. In addition, this study will show there 
will be no statistically significant difference in the clinical outcomes of patients, 
productivity of CSP or projects completed by CLPS between the pre intervention and 
post intervention phases.   
 
Study Design: 
 
This is a retrospective cohort study using a quasi-experimental design, as this design is 
tailored to evaluate the impact of the composite intervention of increased CSP and CLPS 
utilization on the given population.  We will compare outcomes between two arms 
(Appendix 1).  
Data was collected retrospectively using computerized databases from the time period of 
October  1, 2011 to April 1, 2014 for the Northwest, Strawberry, Settegast, and Acres 
Clinics. 
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Methods: 
 
General:   
Computerized databases were used to gather data on anticoagulation visits, time to third 
available appointment and productivity measures. EMR Chart reviews were conducted on 
sampled patients to assess time in therapeutic range and readmissions due to 
thromboembolic event or bleed. CLPS reporting was utilized to assess number of projects 
completed pre and post intervention.   Data was downloaded or documented onto an 
electronic spreadsheet (MS Excel) and analyzed using Student t tests and chi squared 
tests for quantitative endpoints.   
 
Inclusion Criteria 
Patient seen by CLPS between October 2011 to April 2014 
 
Time period 
 
 The post intervention data was collected from March 1, 2014 to April 1, 2014 
 Pre-intervention data was collected 10 days immediately prior to the pilot. 
 
Details of the increased pharmacist utilization intervention   
CLPS in the past did not have scheduled patient visits on Fridays.  Fridays were used for 
staff meetings, student topic discussions, and time allotted for additional projects. To 
increase visit access, two half days of visits per month were added to the clinic sites to 
16 
 
 
 
increase appointment availability beginning April 2013. This would allow for an 
additional 16 to 24 patient visits per month. 
When reviewing patients seen by CLPS, it was noticed that a percentage of the patients 
were chronically managed and therapeutically controlled.   For these patients, the clinical 
outpatient pharmacy team and outpatient pharmacy operations team collaborated to 
implement a pharmacist telephone encounter service designed to help monitor patients on 
warfarin beginning April 2013.  This service was staffed by CSPs. The CSPs monitored 
patients who were therapeutically controlled on warfarin therapy for over three months.  
The telephone visit lasted approximately 15 minutes per patient. Thereafter, the CSP 
scheduled the patient for a follow up PT/INR and telephone appointment. The CSPs at 
each clinic site provided the telephone anticoagulation service with a goal of monitoring 
10 patients per clinic site. Sponsoring physician agreements, per Texas State Board Rule 
295.13 and Texas Medical Examiners Rule 193.7, were signed to allow the clinical staff 
pharmacists to provide anticoagulation telephone management. Appendix 2 and 
Appendix 3 illustrates how patients were referred to the telephone management service 
by CLPS and also, how a patient was returned to CLPS if face to face management was 
deemed necessary.  
 
Power Analysis  
 
The intervention took place during a period from April 1, 2013 to March 31, 2014. 
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This study will retrospectively evaluate the effect of these interventions on total number 
of visits added, time to 3rd available appointment, clinical outcomes, CSP productivity, 
and CLPS projects completed. 
 
A randomly selected cohort of 50 patients will be evaluated per clinic site post 
intervention, for a total of 200 patients post intervention. All patients managed by 
telephone management will be included in the sample. Pre intervention a randomly 
selected cohort of 75 patients per clinic will be evaluated per clinic for a total of 300 
patients pre-intervention.  Patients for the telephone management service will be 
randomly selected and included in the pre intervention group. The total sample size for 
this project will be 500 patients. To analyze our results we will use a student T test for 
continuous data and χ2 tests for categorical data. A p-value of less than <0.05 will be 
considered statistically significant. 
 
Results: 
As shown in Figure 2, across all clinics the total number of visits increased between the 
two periods.  From August 2011 to March 2013, on average the CLPS clinics had 270 
visits per month. An overall 15% increase was seen, and between April 2013 to March 
2014, 312 patients were seen on a monthly basis. This result was statistically significant 
(p=0.006).  In the pre intervention period, anticoagulation visits accounted for roughly 
50% of all visits. During the post intervention period, the anticoagulation visits accounted 
for 46% of all visits. This indicates that visits for other disease states (i.e. Diabetes, Heart 
Failure, Hypertension, etc.) increased between the pre and post intervention period. This 
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is further highlighted in figure 2, as the monthly average for visits regarding other disease 
states increased from 136 visits per month to 169 visits per month. This result is also 
statistically significant (p=.02).  
The primary objective of this study was to assess the total number of anticoagulation 
visits pre and post intervention. At Acres Clinic, the monthly average of anticoagulation 
visits from the time period of August 2011 to March 2013 was 139 patients monthly. This 
number increased to 159 anticoagulation visits monthly during the post intervention 
period from April 2013 to March 2014 (p=0.15). At Northwest however, the increase was 
negligible from an average of 124 to 125 post intervention (p=0.90). At Settegast, a 6.3% 
increase was noted from 157 anticoagulation visits on a monthly basis to 167 
anticoagulation visits on a monthly basis (p=0.50). At Strawberry, visits increased from 
116 to 120 (p=0.76). On average a 6.7% increase in anticoagulation visits was seen pre 
and post intervention across all clinics, from 134 monthly anticoagulation visits post 
intervention to 143 monthly visits post intervention. However the results were not 
statistically significant (p=0.13).   
 
Time to third available appointment, reflects the time for the next available appointment 
with the CLPS. Results are shown above in Table 2 for the average length of time in 
days. On average, at Acres clinic the time to next available appointment was roughly 15 
days during the time period of October 2011 to March 2013. The time to third available 
appointment post intervention decreased from 15 days to 14 days (p=0.73). At Northwest, 
a 41% reduction in time to third available appointment was seen as the length of time 
decreased from 12 days to 7 days, which was a statistically significant result (p < 0.001). 
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A 25% reduction was noted from 12 days to 9 days at Settegast clinic. Finally at 
Strawberry, the length of time to third available appointment remained similar pre and 
post intervention at 14 days. Overall, across all clinics the pre-intervention average length 
of time to third available appointment decreased from 13.2 to 10.8, this was an 18% 
decrease which was not statistically significant (p=0.07).       
 
A total of 501 patients were reviewed, 300 during the pre-intervention period and 201 
during the post intervention period.  Baseline characteristics of patients are noted in 
Tables 3 and 4. Overall, in the pre intervention group time in therapeutic range was 
53.44% compared to 55.8% in the post intervention group as noted in Figure 1.  The 
difference between the pre-intervention period and post intervention period was 
statistically significant (p= 0.04).  
Patients who were hospitalized due to thromboembolic event or bleed, which corresponds 
to 10.6% compared to 6.95% in the post intervention group.  The result was not 
statistically significant as noted in Figure 2 (p value= 0.15).  
 
CSP Productivity is defined as total work hours over total picked up prescriptions. As 
shown in Table 5, no statistical difference was noted between clinic sites for productivity 
during the pre-intervention period compared to the post-intervention period.   
In addition to CSP Productivity, CLPS were able to maintain current projects similar to 
project course load during the pre and post intervention period as shown in Figure 3.  
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Conclusion: 
Results from the post intervention period were positive. An increase was noted in total 
anticoagulation visits; however the result was not statically significant. A 6.8% difference 
in total visits was noted compared to the projected 20% difference in total anticoagulation 
visits. There were several factors that could have contributed to the decreased difference 
margin. Enrollment into the telephone service was slow for several reasons. Many 
patients expressed to the CLPS that they preferred face to face visits or that they did not 
want to have a lab appointment. During CLPS visits, INR was obtained utilizing POC 
testing, however a lab appointment for INR would require a venipuncture. In addition, in 
the CSP telephone service, across all four clinics, a total of 43 patients were enrolled in 
the service. However, by March 2014 only 17 patients remained in the service. Appendix 
5 highlights reasons for why patients were removed, the majority due to having more 
than two INR values outside of therapeutic range. Also, although 16 to 24 patient 
appointments were added to the CLPS schedule, these visits could be utilized for various 
disease states (i.e. diabetes, heart failure, hypertension, etc.) and were not limited to 
anticoagulation alone. This is further highlighted by Figure 2. As shown, total visits has 
increased by 15%, which was statistically significant (p=0.006), and visits for other 
disease states had increased between the two periods (p=0.02).   CLPS Time to third 
appointment was noted to decrease across all clinics, however the result was not 
statistically significant. This may be due to moving patients into the telephone service 
and the additional available slots for CLPS patient visits. However, the only clinic with a 
significantly reduced time to third appointment was Northwest Clinic, therefore there 
may be other confounders affecting the statistical significance, which remain unknown.  
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As noted in the results, hospitalizations due to thromboembolic event remained similar in 
both groups, and therefore no statistical significance was seen. TTR was noted to increase 
in the post intervention group compared to those pre-intervention. Although the result 
was statistically significant, this result is not clinically significant as only a 2% change in 
TTR was seen. This change can possibly be attributed to differences in INR testing 
frequency and patient adherence to visits. The clinics were able to maintain clinical 
outcomes while expanding the clinical responsibilities of the CSPs. Productivity 
standards for both CLPS and CSP were maintained as noted in the results.  
 
This study has several limitations. First of all, this study was unable to meet power as a 
20% difference was not detected between the pre-intervention period and the post-
intervention period. Slow enrollment is multi-factorial and illustrated in Appendix 3. In 
addition to aforementioned reasons, at particular sites, sponsoring agreements were 
difficult to render for CSP telephone anticoagulation service. For example, in certain 
clinics, long wait times and prescription volume burden caused sponsoring physicians to 
be hesitant of agreeing to a new initiative that would remove a CSP away from 
distributive functions for over an hour daily. It was at difficult at times for CSPs to step 
out of the workflow to conduct telephone interviews. In addition, utilization of POC 
testing by CSPs may have aided enrollment into the service, however was not available 
during the time of this study. In regards to clinical outcomes, although INR 
documentation and clinical protocol were similar across all sites, INR follow up may be 
22 
 
 
 
inconsistent or differentiate based on patient adherence to appointments and schedule 
placed by CLPS.      
  
Increasing utilization of CSP and CLPS pharmacists in the outpatient setting allowed for 
expanded coverage in the anticoagulation. No change was noted in clinical outcomes and 
productivity measures were preserved, indicating that the increased workload did not 
hamper performance. When comparing this study to other studies noted in Table 6, we 
noted that the intervention required minimal training and setup. In comparison to other 
studies, such as Wittkowsky et al., and Witt et al. this study required minimal setup as 
training of CSP took roughly 1-2 weeks, the implementation of a telephone service took 
several months to create in the other studies. Therefore, we were able to expand coverage 
through minimal change to workflow and workload.  
 
Further studies should evaluate expanding anticoagulation service from CLPSs to CSPs 
to see if clinical care can be maintained with a larger volume of patients. Due to slow 
enrollment, the telephone service was discontinued on April 1, 2014, and patients being 
seen by CSPs were returned to CLPS to be managed through CLPS.  Additional projects 
have been taken to expand POC anticoagulation coverage through adding additional 
CLPS staff in various locations within the Harris Health System. 
 
The obstacles, challenges and data obtained from the increased utilization period will 
greatly assist in the development of future steps needed to expand anticoagulation 
coverage and service for the Harris Health System and clinical duties for CSPs.    
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Appendix 1: Patient Enrollment for Telephone Encoutner Service 
Patients Referred to Telephone Service Patients ineligible for Telephone Service 
 Patients with three consecutive 
INRs within therapeutic range 
 
 Patient less than 18 years of age 
 Patients discharged within the past 
30 days from the hospital 
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Appendix 2: Removal of Patient from Telephone Encounter Servic
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Figure 1: Treatment Arms 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pre-Intervention Period 
Data from October 1, 2011 to February 28, 
2013 
Monday to Thursday Clinic 
No CSP Telephone Service 
Post Intervention Period 
March 1, 2013 to April 1, 2014 
CSP Telephone Service 
Increased CLPS visits 
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Figure 2: Total Number of Visits 
 
 
 
 
 
 
 
 
 
 
 
 
134 143 
136 
169 
0
50
100
150
200
250
300
350
PRE POST
Total Number of Visits Pre anf Post Intervention 
Average of Number of Visits (Anticoag) Average of Other Visits
30 
 
 
 
 
Table 1: Total Number of Anticoagulation Visits 
Clinic Pre-Intervention 
(Monthly Avg) 
Post Intervention  
(Monthly Avg) 
P-Value CI 
Acres 139 159 0.13 (-6.5 to 46.6) 
Northwest 123 125 0.80 (-13.2 to 17) 
Settegast 157 167 0.48 (-17.3 to 35.9) 
Strawberry 116 122 0.59 (-17 to 29.4) 
All Clinics 134 143 0.15 (-3.4 to 22) 
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Table 2: CLPS Time to Third Available Appointment (Days) 
 
Clinic Pre-Intervention 
(Monthly Avg) 
Post-Intervention 
(Monthly Avg) 
P-Value CI 
Acres 15 14 0.69 (-9.8 to 6.6) 
Northwest 12 7 <0.001 (-7.8 to -2.3) 
Settegast 12 9 0.22 (-7.3 to 1.75) 
Strawberry 13.6 14 0.86 (-5.1 to 4.3) 
All Clinics 13.2 10.8 0.07 (-5.13 to 0.217) 
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Table 3: Baseline Characteristics 
 
Total  
N = 188 
Pre-Intervention 
N=301 
Post-Intervention 
N=201 
P Value 
Male (N) 147 (49%) 110 (55%) .339 
Female (N) 152 (51%) 91 (45%) 
Age in years (median) 59 61  
Ethnicity (N,%)    
White 51 (17%) 35 (17%) .925 
Black 107 (36%) 67 (33%) 
Hispanic 124 (41%) 89 (45%) 
Other 18 (6%) 10 (5%) 
Comorbidities (N,%)    
Diabetes 99 (33%) 61 (30%) .846 
Hypertension 211 (70%) 141 (70%) .846 
Hyperlipidemia 142 (47%) 91 (45%) .585 
Cancer 10 (3.3%) 10 (4.9%) .100 
Heart Failure 71 (27%) 54 (18%) .417 
Obesity 43 (14%) 22 (11%) .269 
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Table 4: Baseline Anticoagulation Characteristics 
 
 Pre 
N = 301 
Post 
N = 201 
P-Value 
Indications for Warfarin    
DVT 50 (17%) 21 (10%) .03 
Atrial Fibrillation  96 (32%) 75 (37%) .24 
PE 14 (5%) 3 (2%) .63 
MMVR/MAVR 58 (19%) 42 (21%) .27 
Lupus 10 (3%) 4 (2%) .37 
Protein S Def 5 (2%) 5 (3%) .52 
Length of Therapy-Indefinite 301 201 1 
INR Goal     
2.0-3.0 239 (79%) 158 (79%) .80 
2.5-3.5 62 (21%) 43 (21%) .80 
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Figure 2: TTR 
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Figure 3: Hospitalizations due to Thromboembolic event or bleed  
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Table 5: CSP Productivity  
Clinic Pre-Intervention (Monthly Avg) Post Intervention  
(Monthly Avg) 
P-Value 
Acres .19 .20 0.17 
Northwest .22 .22 0.58 
Settegast 0.21 0.22 0.92 
Strawberry .22 .22 0.85 
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Figure 8: CLPS Projects 
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Appendix 3: Telephone Service 
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Table 6: Intervention Review 
 
Article Sample 
Size 
Primary Outcome Level Intervention Clinical Outcomes 
Witt et al.
5
 N=6,645 Occurrence of 
anticoagulation 
related 
complication 
Major Creation of a clinical 
pharmacy 
anticoagulation 
service (CPAS). This 
is a telephone 
anticoagulation clinic 
involving clinical 
specialists, staff 
pharmacists and 
technicians. The team 
was also available by 
pager 
24 h per day, 7 days 
per week. 
 30% less likely to 
experience 
anticoagulation event 
 Increased TTR in 
CPAS  
Wittkowsky N=234 Warfarin-related 
monitoring 
outcomes 
Major Telephone-based 
management had 
been selected for 
patients because they 
were unable to be 
seen in person due to 
physical disability, 
the inability to 
arrange or afford 
transportation, the 
fact that they lived a 
great distances from 
the clinic, or were 
unable to wait for a 
face-to-face visit and 
INR blood draws.  
 TTR similar 
 Frequency of clinic 
visits similar 
 No statistical 
difference in  bleed or 
thromboemobolic 
event 
Philip et al.  N= 501 Number of 
anticoagulation 
visits  
Minor Increase number of 
available 
appointments for 
CLPS pharmacists 
Add a telephone 
service for patients 
consistently in 
therapeutic range, 
which was completed 
by CSP pharmacists  
 Increase in number of 
anticoagulation visits, 
but not statistically 
significant 
 No difference in 
clinical outcomes of 
productivity  
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